Travere Therapeutics, Inc. - Special Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : You indicated that you're intending to pursue an accelerated approval submission. Is it safe to assume that results are generally in line with what you've previously discussed with the FDA? Or are your plans to reengage regulators to discuss anything specific in the data set that you're -- that you've observed?

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : Okay. And if I could, just one more. It looks like the placebo arm outperformed some investor expectations. I am just curious if what you saw in these results on the proteinuria changes or evolves the way that you think about the study in IgA nephropathy at all?

Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst : And then congrats on the data. I guess my first question is when you look at the FPRE results at this interim analysis, how do you think about the assumptions that you made for the eGFR confirmatory endpoint and the statistical powering around that? Did you account for this level of difference in FPRE?

Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst : Great. And as we think about the IgA nephropathy data in the third quarter, are there any takeaways that we could look at the FSGS proteinuria data and apply it to the upcoming IgAN trial?

Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst : Okay. And then last question. Could you comment on how the dose titration worked in the study? Did it go and prevent the dose interruptions and reductions that you saw in the Phase II?